ILLUMINA, INC.

ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

About the company

Country: United StatesPrice: $207.01Market Cap: $31.3B

Investment snapshot

35%positive consensus

Scored 1d ago

Positive

BUY / PASS

Neutral / negative

2 / 8

NEUTRAL / FAIL

Median fair value

$63.39

-69.4% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

6 of 10 pass — Dreman, Pabrai, Ackman +1 more object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

Verdict	Meaning
BUY	Positive purchase signal: the framework's buy requirements are met.
PASS	The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRAL	Neither a positive nor negative conclusion. It does not mean to hold an existing position.
FAIL	The company does not clear the framework's requirements.
Ranked	Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

Metric	Graham Defensive Value	Buffett Quality Compounder	Lynch GARP	Greenblatt Magic Formula	Piotroski F-Score	Dreman Contrarian Value	Munger Quality Focus	Pabrai Dhandho Framework	Akre Three-Legged Stool	Marks Risk-Aware Value	Ackman Activist Value	Templeton Global Bargain Hunter	Sleep Scale Economies Shared	Asness Systematic Factors	Neff Low-P/E Total Return	Schloss Asset-Value Discipline	O'Shaughnessy Systematic Factor Composite
Verdict	FAIL	FAIL	FAIL	FAIL · Rank #1016 (Top 32.8%)	BUY	PASS	PASS	FAIL	FAIL	FAIL	NEUTRAL	PASS	PASS	BUY	FAIL	FAIL	NEUTRAL
Score
Analysis	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…
Intrinsic Value (annual)				N/A	N/A	N/A				N/A		N/A	N/A	N/A	N/A	N/A	N/A
Margin of Safety	-343.1%	-175.7%	-818.0%	N/A	N/A	N/A	-218.2%	-334.9%	-140.1%	N/A	-226.5%	N/A	N/A	N/A	N/A	N/A	N/A
Financial Basis	TTM ended 2026-09-27 · Balance sheet at 2026-09-27 · Annual history · FY 2025 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · Balance sheet at 2026-09-27 · TTM ended 2026-09-27 vs 2025-09-28 · TTM ended 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-02-12 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-02-12 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-27 · Balance sheet at 2026-09-27 · Market data at 2026-11-01 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-27 · Balance sheet at 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-12 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-27 · Balance sheet at 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-12 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-27 · Balance sheet at 2026-09-27 · Market data at 2026-11-01 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-12 Score computed: 2026-11-14	TTM ended 2026-09-27 · Balance sheet at 2026-09-27 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	Annual history · FY 2025 · Balance sheet at 2026-09-27 Latest source filing: 2026-10-30 Score computed: 2026-11-14	TTM ended 2026-09-27 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-10-30 Score computed: 2026-11-14

Where It Passes

Cash Flow60% pass✓ 7✗ 5▾
6 of 10 pass — Dreman, Pabrai, Ackman +1 more object
Free Cash Flow Proxy$972.0M
✓BuffettPositive and growing
FCF Positive and Growing$1.1B
✓LynchPositive and growing
Operating Cash Flow$1.1B
✓PiotroskiCFO > 0
(CFO / Total Assets) vs ROACFO/Assets=16.24%, ROA=12.79%
✓PiotroskiCFO/Assets > ROA
Price / (CFO / Shares)29.4x
✗Dreman< 8x
P/E or FCF YieldP/E=38.0x, FCF Yield=3.0%
✗PabraiP/E < 15 or FCF Yield > 10%
FCF Positive18/18 years FCF positive
✓MarksPositive FCF in majority of recent years
(OCF - CapEx) / Market Cap3.3%
✗Ackman>= 4%
Price / FCF per Share34.0x
✗Ackman<= 25
Positive Operating Cash Flow frequency20/20 years positive
✓SleepPositive OCF in >= 70% of available years
Operating Cash Flow - Capital Expenditures$1.1B
✓Neff> $0 (app proxy for a strong fundamental case)
(Operating cash flow - capex) / market capitalization+3.38%; #1965/4519 (top 43.5%)
✗OshaughnessyTop 10% of eligible cross-section

Where It Falls Short

Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS
✗Graham<= 15x
Price-to-Book Ratio11.6x
✗Graham<= 1.5x
P/E x P/B
✗Graham<= 22.5
Basic earnings-growth PEG (dividends excluded)9.18
✗Lynch< 1.0 (ideally < 0.5)
EBIT / Enterprise Value2.5%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=2.5%, ROC=77.2%
✗GreenblattBoth EY > 10% and ROC > 25%
Price / EPS38.0x
✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
Price / (CFO / Shares)29.4x
✗Dreman< 8x
Price / Book Value per Share11.6x
✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
Valuation ReasonablenessP/E=38.0x, OE Yield=3.1%
✗MungerP/E < 25 or Owner Earnings Yield > 5%
P/E or FCF YieldP/E=38.0x, FCF Yield=3.0%
✗PabraiP/E < 15 or FCF Yield > 10%
P/B or P/E vs. Historical AverageP/E=38.0x, P/B=11.6x
✗MarksP/E < 15 or P/B < 2.0
Discount to Intrinsic ValueN/A (negative normalized EPS)
✗Marks>= 20% below intrinsic value
Price / FCF per Share34.0x
✗Ackman<= 25
Price vs. Trailing Low267% of trailing low ($77.60)
✗Templeton<= 120% of trailing low (certified split-adjusted live window)
Net income / market capitalization+2.86%; #2424/6340 (top 38.2%)
✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Positive book equity / market capitalization+0.1005; #4741/6449 (top 73.5%)
✗AsnessTop 30% of eligible cross-section
Price / Diluted EPS38.0x
✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
(EPS CAGR % + Dividend Yield %) / P/E
✗Neff> 0.7 (Neff's published traditional edge)
Price / Tangible Book Value per Share22.62x
✗SchlossP/TBV <= 1.00x (app cutoff)
Book Value per Share Change-44.6%
✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
Revenue / market capitalization+0.1450; #4084/5247 (top 77.8%)
✗OshaughnessyTop 10% of eligible cross-section
(Operating cash flow - capex) / market capitalization+3.38%; #1965/4519 (top 43.5%)
✗OshaughnessyTop 10% of eligible cross-section
Trailing six-month price return through the evaluation date+71.18%; #484/6202 (top 7.8%)
✓OshaughnessyTop 10% of eligible cross-section
Valuation models0% pass✗ 7▾
ILMN overvalued: all 7 models price fair value below $207.01 (median $63.39)
Graham fair value$46.72
✗Graham-343.1% margin vs $207.01
Buffett fair value$75.08
✗Buffett-175.7% margin vs $207.01
Lynch fair value$22.55
✗Lynch-818.0% margin vs $207.01
Munger fair value$65.06
✗Munger-218.2% margin vs $207.01
Pabrai fair value$47.60
✗Pabrai-334.9% margin vs $207.01
Akre fair value$86.23
✗Akre-140.1% margin vs $207.01
Ackman fair value$63.39
✗Ackman-226.5% margin vs $207.01
Growth25% pass✓ 4✗ 9▾
6 of 8 flag ILMN's growth — Graham, Lynch, Dreman +3 more
EPS Growth (3-yr avg, 10-yr window)-100.3%
✗Graham>= 33% growth
Basic earnings-growth PEG (dividends excluded)9.18
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR4.1%
✓Lynch15-30% (Fast Grower); > 0% to pass
Inventory Growth vs Revenue GrowthInv: 13.1% vs Rev: 5.8%
✗LynchInventory growth < Revenue growth
EPS Growth Direction$669.00 (1998) -> $5.45 (2025)
✗DremanPositive over recent years
EPS CAGR-16.3% CAGR over 27 years
✗Dreman> 5% annualized
Positive Net Income Frequency17/20 years positive
✓MarksPositive net income in >= 7 of last 10 years
3yr Median Revenue Growth-1.7%
✗Ackman>= 5%
Positive EPS Growth Frequency3/5 years with positive EPS growth
✓AckmanPositive EPS growth in >= 3 of last 5 years
5-Year EPS CAGR4.1% CAGR over 5 years
✓Templeton> 0% (5-year EPS CAGR)
Revenue growth vs. gross and operating margin trendgross margin 60.9% -> 66.1%, operating margin -23.7% -> 18.6%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
5-year Revenue CAGR6.0%
✗SleepCAGR > 7%
3-5 Year Diluted EPS CAGR4.1% over 5 years
✗Neff7%-20% annualized
Profitability31% pass✓ 17✗ 18▾
11 of 16 flag ILMN's profitability — Graham, Buffett, Lynch +8 more
Positive EPS (10 years)17/27 years positive
✗GrahamPositive EPS every year for 10 years
EPS Growth (3-yr avg, 10-yr window)-100.3%
✗Graham>= 33% growth
Net Income Positive (10+ years)17/27 years positive
✗BuffettPositive every year for 10+ years
ROE (up to 5-year arithmetic mean)-20.0%
✗Buffett> 15% arithmetic mean (app rule)
Operating Margin (10-yr trend)18.6% (latest)
✗BuffettStable or rising over 10 years
Free Cash Flow Proxy$972.0M
✓BuffettPositive and growing
Earnings Variance (10-yr CoV)3.20
✗BuffettCoV < 0.3
Retained Earnings Effectiveness
✗Buffett$1 retained -> > $1 market value created
Basic earnings-growth PEG (dividends excluded)9.18
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR4.1%
✓Lynch15-30% (Fast Grower); > 0% to pass
ROE28.5%
✓Lynch> 15%
EBIT / Enterprise Value2.5%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=2.5%, ROC=77.2%
✗GreenblattBoth EY > 10% and ROC > 25%
Net Income / Total Assets12.79%
✓PiotroskiROA > 0
ROA Change YoY-19.40% -> 12.79% (delta: +32.20%)
✓PiotroskiCurrent ROA > Prior ROA
(CFO / Total Assets) vs ROACFO/Assets=16.24%, ROA=12.79%
✓PiotroskiCFO/Assets > ROA
Gross Margin Change YoY65.4% -> 66.1%
✓PiotroskiImproved YoY
Pre-Tax Income / Revenue23.3%
✓Dreman>= 8%
Net Income / Shareholders' Equity28.5%
✓Dreman> 12%
Margin of SafetyP/E=38.0x, P/B=11.6x
✗PabraiP/B < 1.5 or P/E < 15
Return on Equity-13.5% (3-yr avg)
✗AkreROE > 20% (3-year avg)
Discount to Intrinsic ValueN/A (negative normalized EPS)
✗Marks>= 20% below intrinsic value
Positive Net Income Frequency17/20 years positive
✓MarksPositive net income in >= 7 of last 10 years
Operating Income / Revenue21.2%
✓Ackman>= 15%
Net Income / Shareholders Equity28.5%
✓Ackman>= 15%
5-Year EPS CAGR4.1% CAGR over 5 years
✓Templeton> 0% (5-year EPS CAGR)
Operating Margin Trend-23.7% (2023) -> 18.6% (2025)
✓TempletonNon-negative operating-margin trend over 3 years
Revenue growth vs. gross and operating margin trendgross margin 60.9% -> 66.1%, operating margin -23.7% -> 18.6%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
Net income / market capitalization+2.86%; #2424/6340 (top 38.2%)
✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Gross profit / total assets+45.21%; #794/3702 (top 21.4%)
✓AsnessTop 30% of eligible cross-section
Net income / positive book equity+28.46%; #482/5226 (top 9.2%)
✓AsnessTop 30% of eligible cross-section
Negative 5-year standard deviation of ROA-0.1737; #4075/5884 (top 69.3%)
✗AsnessTop 30% of eligible cross-section
3-5 Year Diluted EPS CAGR4.1% over 5 years
✗Neff7%-20% annualized
Positive Diluted-EPS Years7/10 years positive
✓Schloss>= 70% positive over 5-10 observed years (app rule)
Verdicts40% pass✓ 6✗ 9▾
Split decision: 8 FAIL · 4 PASS · 2 BUY · 2 NEUTRAL
Overall verdict
✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)✗GreenblattRank #1016✓PiotroskiBUY (F-Score 8)✓DremanPASS (5/11)✓MungerPASS (2/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (3/5)•AckmanNEUTRAL (6/9)✓TempletonPASS (4/8)✓SleepPASS (3/6)✓AsnessBUY (Rank #672/2370 (Top 28.4%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
Debt & Leverage50% pass✓ 8✗ 7▾
6 of 12 pass — Graham, Buffett, Lynch +3 more object
LT Debt vs Net Current Assets
✗GrahamLT Debt <= Net Current Assets
Debt/Equity & Interest CoverageD/E: 0.57, IC: 9.8x
✗BuffettD/E < 0.5 AND Interest Coverage > 5x
Total Debt / Equity0.57
✗Lynch< 0.33
Cash - Long-term Debt
✗LynchPositive preferred
LT Debt / Total Assets Change0.00% -> 0.00%
✓PiotroskiDecreased YoY
Current Assets / Current Liabilities2.63
✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
Total Debt / Shareholders' Equity0.57
✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
Debt Levels0.57
✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
Interest Coverage & Debt/EBITDAIC=8.5x, D/EBITDA=1.8x
✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
Total Debt / Shareholders Equity0.57
✓Ackman<= 1.0
Negative debt-to-equity (higher means less debt)-0.5688; #2603/4210 (top 61.8%)
✗AsnessTop 30% of eligible cross-section
Efficiency50% pass✓ 6✗ 5▾
4 of 8 pass — Buffett, Piotroski, Akre +1 more object
Current Ratio2.63
✓Graham>= 2.0
ROIC (3-5 yr avg)-16.1%
✗Buffett> 10%
ROIC - WACC-26.1%
✗BuffettPositive (WACC = 10%)
EBIT / (NWC + Net Fixed Assets)77.2%
✓Greenblatt> 25%
Current Ratio Change YoY1.78 -> 2.08
✓PiotroskiIncreased YoY
Revenue / Total Assets Change YoY0.69x -> 0.65x
✗PiotroskiImproved YoY
Current Assets / Current Liabilities2.63
✓Dreman> 1.5
Return on Invested Capital15.4%
✓Munger> 15%
ROIC (high and growing)FY2023: ROIC=-11.7%; FY2024: ROIC=-15.1%; FY2025: ROIC=13.5%
✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
Reinvestment Rate x ROIC13.5% (RR=100% x ROIC=13.5%)
✓AkreReinvestment Rate * ROIC > 10%
ROIC (5-year)1/5 years above 12% (latest 13.5%)
✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Measuring and Control Equipment

SIC Sector: Measuring & Medical Instruments

Size: Large Cap($31.3B)

Revenue: $4.3B-0.7% YoY

Net Income: $850.0M+169.5% YoY

Financial Snapshot

Operating Margin18.6%

Return on Equity31.2%

Debt / Equity0.73

Current Ratio2.08

EPS (Diluted)$5.45

Buybacks (1y)$742.0M

Buybacks (2y)$858.0M

Shares Retired3.8% / 3.8% 2y

Similar Companies

TMOTHERMO FISHER SCIENTIFIC INC.

AAGILENT TECHNOLOGIES, INC.

$49.0B

Shareholder Return

Fiscal 2025

Retired 3.8% of shares last year, 3.8% over two.

Buybacks: $742.0M
Dividends: —

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

Metric	TTM · 2026-09-27 2025-09-29 – 2026-09-27 Sources · derived quarter values 10-K · 2026-02-12 10-Q · 2026-05-04 10-Q · 2026-07-31 10-Q · 2026-10-30 Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks.	Q3 FY 2026 2026-06-29 – 2026-09-27 Sources · derived quarter values 10-Q · 2026-10-30 Derived from cumulative filings: operating cash flow, capex, buybacks.	Q2 FY 2026 2026-03-30 – 2026-06-28 Sources · derived quarter values 10-Q · 2026-07-31 Derived from cumulative filings: operating cash flow, capex, buybacks.	Q1 FY 2026 2025-12-29 – 2026-03-29 Sources 10-Q · 2026-05-04	FY 2025 Sources 10-K · 2026-02-12	FY 2024 Sources 10-K · 2025-02-12	FY 2023 Sources 10-K · 2024-02-16	FY 2022 Sources 10-K · 2023-02-17	FY 2021 Sources 10-K · 2022-02-18
Market Cap	$31.3Bcurrent	--	--	--	$22.2Best.	$21.1Best.	$22.1Best.	$32.9Best.	$53.3Best.
Revenue	$4.5B↑6%	$1.1B↑4%	$1.2B↑9%	$1.1B↑5%	$4.3B↓1%	$4.4B↓3%	$4.5B↓2%	$4.6B↑1%	$4.5B
Operating Income	$960.0M↑23%	$305.0M↑34%	$245.0M↑14%	$209.0M↑27%	$807.0M↑197%	-$833.0M↑22%	-$1.1B↑74%	-$4.2B↓3298%	-$123.0M
Net Income	$895.0M↑27%	$220.0M↑47%	$207.0M↓12%	$134.0M↑2%	$850.0M↑170%	-$1.2B↓5%	-$1.2B↑74%	-$4.4B↓678%	$762.0M
EPS (Diluted)	--	$1.43↑46%	$1.35↓9%	$0.87↑6%	$5.45↑171%	$-7.69↓5%	$-7.34↑74%	$-28.00↓656%	$5.04
Gross Margin	67.9%↑3%	73.5%↑9%	66.4%↑1%	66.1%↑1%	66.1%↑1%	65.4%↑7%	60.9%↓6%	64.8%↓7%	69.7%
Operating Margin	21.2%↑16%	27.0%↑29%	21.1%↑5%	19.2%↑22%	18.6%↑198%	-19.1%↑20%	-23.7%↑74%	-91.2%↓3255%	-2.7%
ROE	28.5%↓4%	—	—	—	31.2%↑161%	-51.5%↓155%	-20.2%↑70%	-66.7%↓1041%	7.1%
Total Debt	$1.8B↓10%	$1.8B↓10%	$2.0B	$2.0B	$2.0B	$2.0B↑34%	$1.5B↑198%	$500.0M↓29%	$702.0M
Shareholders' Equity	$3.1B↑32%	$3.1B↑32%	$2.8B↑26%	$2.7B↑13%	$2.7B↑15%	$2.4B↓59%	$5.7B↓13%	$6.6B↓39%	$10.7B
Current Ratio	2.63↑84%	2.63↑84%	1.80↓1%	1.75↓6%	2.08↑17%	1.78↑7%	1.66↑29%	1.28↓48%	2.48
Debt / Equity	0.57↓32%	0.57↓32%	0.70↓20%	0.74↓12%	0.73↓13%	0.84↑223%	0.26↑242%	0.08↑16%	0.07
Operating Cash Flow	$1.2B↑10%	$419.0M↑48%	$201.0M↓14%	$289.0M↑20%	$1.1B↑29%	$837.0M↑75%	$478.0M↑22%	$392.0M↓28%	$545.0M
Free Cash Flow	$1.1B↑6%	$379.0M↑50%	$161.0M↓21%	$251.0M↑21%	$931.0M↑31%	$709.0M↑151%	$283.0M↑167%	$106.0M↓69%	$337.0M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Measuring and Control Equipment

ILMN vs Peers — Financial Grading

Revenue$4.3BMedian

Net Income$850.0MMedian

ROE31.2%Top 25%

D/E0.73Bottom 25%

Op. Margin18.6%Median

Curr. Ratio2.08Top 25%

Company	Market Cap	Price	Revenue	Net Income	ROE	D/E	Op. Margin	Curr. Ratio	Graham	Buffett	Lynch	Greenblatt	Piotroski	Dreman
THERMO FISHER SCIENTIFIC INC.TMO	$259.4B	$700.22	$44.6B	$6.7B	12.6%	0.74	17.4%	1.89	3/9	3/9	3/7	1/3	F-Score 5	7/11
DANAHER CORP /DE/DHR	$163.9B	$233.02	$24.6B	$3.6B	6.9%	0.35	19.1%	1.87	3/9	4/9	2/7	1/3	F-Score 5	4/11
WATERS CORP /DE/WAT	$90.5B	$460.25	$3.2B	$642.6M	25.1%	0.55	25.4%	1.73	1/9	4/9	1/7	0/3	F-Score 4	5/11
AGILENT TECHNOLOGIES, INC.A	$49.0B	$173.96	$6.9B	$1.3B	19.3%	0.45	21.3%	1.96	2/9	5/9	3/7	1/3	F-Score 5	5/11
ROPER TECHNOLOGIES INCROP	$47.5B	$479.98	$7.9B	$1.5B	7.7%	0.47	28.3%	0.52	2/9	3/9	3/7	0/3	F-Score 6	4/11
COHERENT CORP.COHR	$43.0B	$218.15	$5.8B	$49.4M	0.9%	0.69	1.6%	2.19	3/9	1/9	0/7	0/3	F-Score 4	4/11
TERADYNE, INCTER	$39.0B	$249.55	$3.2B	$554.0M	19.8%	0.07	20.4%	1.75	2/9	6/9	4/7	1/3	F-Score 6	6/11
MKS INCMKSI	$14.6B	$215.65	$3.9B	$295.0M	10.8%	1.53	13.4%	2.71	2/9	2/9	3/7	1/3	F-Score 7	6/11

25 fiscal years have an unverified share basis

FY1998, FY1999, FY2000, FY2001, FY2002, FY2003, FY2005, FY2006, FY2007, FY2008, FY2009, FY2010, FY2011, FY2012, FY2013, FY2014, FY2015, FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022 and FY2023 could not be reconciled between the historical share price and the per-share figures reported for those years. Splits and ADS re-bundlings change what “one share” means, and the two sides are not always restated together — so ratios for those years, including P/E, P/B and margin of safety, may be scaled by a whole-number factor. Other years on this page are unaffected.

Across the whole archive, 81.5% of company-years reconcile and 18.5% do not. Unverified years are shown rather than silently corrected, because a guessed adjustment is worse than a flagged one.